Natera (NTRA) Gets a Buy from RBC Capital
TipRanks (Tue, 8-Apr 9:50 PM ET)
DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting
Business Wire (Tue, 25-Mar 7:00 AM ET)
Business Wire (Mon, 10-Mar 8:00 AM ET)
Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD
Business Wire (Tue, 4-Mar 7:00 AM ET)
Natera Announces Medicare Coverage of Signatera for Surveillance in Lung Cancer
Business Wire (Tue, 25-Feb 6:00 AM ET)
Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025
Business Wire (Tue, 18-Feb 9:00 AM ET)
NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma
Business Wire (Mon, 10-Feb 7:00 AM ET)
Natera Announces National Commercial Coverage for its Fetal RhD NIPT
Business Wire (Mon, 3-Feb 7:00 AM ET)
Business Wire (Sat, 25-Jan 10:05 AM ET)
Natera to Present New Data at the 2025 ASCO GI Symposium
Business Wire (Tue, 21-Jan 6:05 PM ET)
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Natera trades on the NASDAQ stock market under the symbol NTRA.
As of April 9, 2025, NTRA stock price climbed to $151.97 with 2,843,138 million shares trading.
NTRA has a beta of 1.17, meaning it tends to be more sensitive to market movements. NTRA has a correlation of 0.21 to the broad based SPY ETF.
NTRA has a market cap of $20.54 billion. This is considered a Large Cap stock.
Last quarter Natera reported $476 million in Revenue and -$.41 earnings per share. This beat revenue expectation by $48 million and missed earnings estimates by -$.02.
In the last 3 years, NTRA traded as high as $183.00 and as low as $27.35.
The top ETF exchange traded funds that NTRA belongs to (by Net Assets): VTI, VB, VXF, VBK, XBI.
NTRA has outperformed the market in the last year with a price return of +59.2% while the SPY ETF gained +7.1%. However, in the short term, NTRA had mixed performance relative to the market. It has underperformed in the last 3 months, returning -14.0% vs -6.6% return in SPY. But in the last 2 weeks, NTRA shares have fared better than the market returning -1.7% compared to SPY -4.7%.
NTRA support price is $127.32 and resistance is $137.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NTRA shares will trade within this expected range on the day.